New research funded by Tickled Pink gives new hope to thousands
Breast Cancer Campaign has made an exciting new research development that could improve the outcomes for thousands of women diagnosed with a certain type of breast cancer.
Work by Breast Cancer Campaign fellow Dr Rob Clarke, funded by Tickled Pink, suggests that breast cancer stem cells from patients can be directly targeted with a new drug in development, effectively stopping the root of the breast cancer within the tumour.
Dr Clarke’s new findings give hope that new treatments could be developed, which would knock out cancer stem cells responsible for breast cancer recurring and spreading.
The research focuses on HER-2 positive – a form of breast cancer which affects roughly 30% of those diagnosed with the disease. Dr Clarke’s new approach also indicates that targeting a particular molecule has the potential to stop all types of breast cancer recurring and spreading as well as other cancers and so may benefit many other patients.
Dr Clarke said: “Breast cancer stem cells hold the key to vital new approaches and treatments to help us beat breast cancer once and for all. We’re making progress every day but we can only get there with charities like Breast Cancer Campaign and their support of our work.”
Dr Clarke was the first breast cancer researcher in the UK to be awarded a Breast Cancer Campaign Scientific Fellowship. Together with co-author of Clinical Cancer Research Journal’s new findings, Dr Gillian Farnie, he has been funded by our Tickled Pink campaign – which contributes £1 million to breast stem cell research in the UK every year.
Read more on the Breast Cancer Campaign website.